BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salewski I, Henne J, Engster L, Schneider B, Lemcke H, Skorska A, Berlin P, Henze L, Junghanss C, Maletzki C. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors. Int J Mol Sci 2021;22:5990. [PMID: 34206051 DOI: 10.3390/ijms22115990] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Salewski I, Henne J, Engster L, Krone P, Schneider B, Redwanz C, Lemcke H, Henze L, Junghanss C, Maletzki C. CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors. OncoImmunology 2022;11:2094583. [DOI: 10.1080/2162402x.2022.2094583] [Reference Citation Analysis]
2 Huang H, Peng L, Zhang B, Till BG, Yang Y, Zhang X, Zhao L, Fu X, Li T, Han L, Qin P, Chen L, Yan X, Liu Y, Wang W, Ye Z, Li H, Gao Q, Wang Z. Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies. Front Immunol 2022;13:882172. [DOI: 10.3389/fimmu.2022.882172] [Reference Citation Analysis]
3 Xu J, Wei X, Wang Y, Wang F. Current status and advances of immunotherapy in nasopharyngeal carcinoma. Ther Adv Med Oncol 2022;14:175883592210962. [DOI: 10.1177/17588359221096214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Principe DR, Kamath SD, Korc M, Munshi HG. The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. Pharmacol Ther 2022;236:108111. [PMID: 35016920 DOI: 10.1016/j.pharmthera.2022.108111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
5 Vafaei S, Zekiy AO, Khanamir RA, Zaman BA, Ghayourvahdat A, Azimizonuzi H, Zamani M. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int 2022;22:2. [PMID: 34980128 DOI: 10.1186/s12935-021-02407-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
6 Li Y, Qiao K, Zhang X, Liu H, Zhang H, Li Z, Liu Y, Sun T. Targeting myeloid-derived suppressor cells to attenuate vasculogenic mimicry and synergistically enhance the anti-tumor effect of PD-1 inhibitor. iScience 2021;24:103392. [PMID: 34841231 DOI: 10.1016/j.isci.2021.103392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]